Alembic Pharma (APLLTD) Share News & Alerts
Every article that mentions APLLTD is analysed by our AI, which assigns a sentiment and tracks the actual price move after the alert fires.
Alembic Pharma gains after receiving USFDA nod for Tretinoin Cream
▲ Bullish +0.23%
The USFDA approval for generic Tretinoin Cream unlocks access to a material $94 million market in the US. This regulatory milestone provides clear multi-day visibility for revenue expansion in the generics portfolio, which is expected to support a bullish swing trade over the short-to-medium term.
Alembic Pharma gains after receiving USFDA nod for Larotrectinib Capsules
▲ Bullish +1.88%
Alembic Pharmaceuticals (APLLTD) has received a tentative nod from the USFDA for generic Larotrectinib capsules, which target a $91 million US oncology market. Being a generic variant of Vitrakvi with Paragraph IV certification, this positions the firm for a potential 180-day market exclusivity period upon final approval. This structural margin catalyst is expected to drive positive multi-day momentum for the stock, presenting a strong setup for swing and positional long trades.
Alembic Pharma receives USFDA approval for Haloperidol tablets
▲ Bullish +2.87%
Alembic Pharmaceuticals (APLLTD) is directly impacted because the final USFDA approval for Haloperidol tablets expands its product portfolio in the lucrative US central nervous system market. The addressable market size of 27 million USD presents a stable, near-term revenue generation stream for the company's US formulations business. This fundamental catalyst is likely to trigger a bullish breakout or steady positive movement for swing and positional traders over a 1-to-2 week timeframe as market sentiment turns constructive on its US business.
Alembic Pharma gains after Q4 PAT climbs 29% YoY to Rs 203 cr
▲ Bullish —
The 29% PAT growth to Rs 203 crore significantly beats the upper end of analyst estimates (Rs 175-200 cr), signaling superior operational efficiency. Furthermore, the entry into the US branded segment with 'Pivya' and a higher-than-expected dividend of Rs 12 per share provide a structural re-rating catalyst for positional traders. Given the robust earnings quality and margin expansion, the stock is likely to see a multi-day upward trend as brokerage targets are revised upward.
Get real-time alerts for APLLTD
Add APLLTD to your portfolio and receive instant AI-powered news alerts on your phone.
Set up free alerts →Explore More
AI Technical Analysis Alert History Other Bullish Stocks Today’s Trending